Omeros Corporation (OMER) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-31

How it makes money

Omeros earns revenue from commercial sales of YARTEMLEA and from licensing and milestone agreements with pharmaceutical partners like Novo Nordisk.

Omeros generates revenue through two primary pathways following the commercial launch of YARTEMLEA in January 2026 for hematopoietic stem cell transplant-associated thrombotic microangiopathy. YARTEMLEA sales depend on physician adoption, patient access, and favorable coverage from government and private payers.

Additionally, Omeros monetizes its discovery pipeline through major licensing transactions, such as the agreement with Novo Nordisk for zaltenibart, which provided an upfront cash payment of $240.0 million alongside future development, regulatory, and sales-based milestones and tiered royalties.

What protects it: the moat

Omeros relies on patent protection and regulatory designations like orphan drug status to defend its therapeutics from generic and branded competition.

Management asserts that YARTEMLEA is the first and only approved therapy for TA-TMA, operating as a selective inhibitor of MASP-2 without requiring prior vaccinations or carrying a boxed warning. The European Commission has also granted narsoplimab orphan medicinal product designation.

However, these protective advantages depend heavily on maintaining valid patents, securing broad regulatory approvals in international markets such as the European Union through the EMA, and successfully defending intellectual property against competitors in the biotechnology sector.

What could damage it

If third-party payers deny coverage or reimbursement for YARTEMLEA, revenue generation would stall and permanently impair the company's financial condition.

YARTEMLEA represents the sole commercial product supporting Omeros in its early commercial stage. If government and private healthcare payers refuse to grant adequate coverage or establish restrictive reimbursement policies, prescribing physicians will be discouraged from utilizing the therapy. Without high uptake and favorable reimbursement rates, Omeros cannot recoup its development costs or sustain operations.

About Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Other companies in Biotechnology